Sarepta's Duchenne gene therapy misses main goal in late-stage study; shares fall - TradingView

Reuters | Nov. 3, 2025, 4:27 p.m. | Original
Sarepta's Duchenne gene therapy misses main goal in late-stage study; shares fall TradingView
Hims and Hers beats revenue estimates on strong subscriber growth - TradingView Crescent to sell Rockies assets to Aethel for $400 million - Bloomberg News - TradingView